FierceBiotech |
FDA clears Juno to resume CAR-T trial
FierceBiotech Juno Therapeutics ($JUNO) was up by about 25% in after-hours trading on news that the FDA has already given it permission to resume the Phase II trial for its JCAR015 that it halted last week. The biotech will continue the trial, as it had hoped, with ... Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial FDA Lifts Clinical Hold on Phase II Trial of JCAR015 in ALL Study of promising cancer treatment allowed to resume |
from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNG6KDmmbjMPCRbvd3Gxplxg38jnQg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779153945912&ei=KGuFV7DINpDI3gGlloL4BA&url=http://www.fiercebiotech.com/biotech/fda-clears-juno-to-resume-car-t-trial
via IFTTT
No comments:
Post a Comment